STANDARD BIOTOOLS INC. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 62/100
What the filing says
Standard BioTools reported Q2 2026 revenue of $20.1M (down 7.6% YoY from $21.8M), with net loss from continuing operations of $21.5M vs. $17.7M prior year. Key developments: (1) Treeline Biosciences merger progressing toward stockholder vote, expected to close before year-end 2026; (2) company agreed to divest Mass Cytometry business; (3) Illumina early buyout of contingent payments for $30M from its SomaLogic acquisition; (4) adjusted EBITDA improved 84% YoY to loss of $2.5M vs. loss of $16.1M; (5) cash position strengthened to $541.1M (including investments) from $227.9M YoY, driven by $388.2M received from sale of business in H1 2026; (6) full year 2026 revenue outlook withdrawn due to pending merger.
Why this rating
Merger is transformational event for a $291M company, but heavily contingent on stockholder approval and regulatory closure. $30M Illumina payment and strong cash position offset operational deterioration (revenue decline, transaction costs). Significance reflects material pending deal with business outcome uncertainty.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.